Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.
about
LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancerAndrogen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cellsAndrogen receptor variants occur frequently in castration resistant prostate cancer metastasesMST1 is a multifunctional caspase-independent inhibitor of androgenic signaling.An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progressionAntitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancerPhase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancerEBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistanceSulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cellsSuppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamideGaleterone for the treatment of advanced prostate cancer: the evidence to dateSplice Variants of Androgen Receptor and Prostate CancerSequence of treatment in locally advanced and metastatic renal cell carcinomaPersistent androgen receptor addiction in castration-resistant prostate cancerNotes for developing a molecular test for the full characterization of circulating tumor cellsAbiraterone in the management of castration-resistant prostate cancer prior to chemotherapyCirculating tumors cells as biomarkers: progress toward biomarker qualificationAbiraterone in the treatment of metastatic castration-resistant prostate cancerβ2-Microglobulin-mediated signaling as a target for cancer therapyThe potential of ¹¹C-acetate PET for monitoring the Fatty acid synthesis pathway in TumorsThe role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancerProstate cancer relevant antigens and enzymes for targeted drug deliveryIntense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesisCCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitorsA surface on the androgen receptor that allosterically regulates coactivator bindingThe importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistancePharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and EnzalutamideMetastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapyThe combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory studyMetabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cellsA multiscale, mechanism-driven, dynamic model for the effects of 5α-reductase inhibition on prostate maintenanceEffect of small molecules modulating androgen receptor (SARMs) in human prostate cancer modelsConcurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expressionAbiraterone and increased survival in metastatic prostate cancerPharmacologic blockade and genetic deletion of androgen receptor attenuates aortic aneurysm formation.SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells.
P2860
Q21202034-9D731C83-819C-49AA-A485-AEA67B6E819EQ21245730-713EB50B-22DC-439A-923D-0ACC41077813Q21558502-F40782DE-5734-46D3-8A96-51200F3CE7BDQ24300132-CDFC3CDF-F6A2-488C-A2D9-EB5F89F6149AQ24313269-D081B3D2-2111-4911-8CEA-0373340C9ED8Q24596926-B143DD43-1885-4432-9C54-2F09CCBED711Q24605577-035A9D40-47E3-4B20-8744-CD4583A840D8Q24627700-10EDA5CF-B8B7-4B4C-AE00-D3B25FC36E54Q24646417-4DB433D1-D99A-42A2-A197-FD17EE76B8CEQ24656643-CE9D8532-BBF2-4413-897C-D04DB8FE3568Q24657502-51642D14-9EC1-4CA2-9170-E2DED64F6FA2Q24669875-53FBDD59-9C01-479A-973C-3A5DC7B9C9EDQ26739887-8F1943C6-1A76-4570-BD7A-2F3C932DE8F3Q26740592-79AB7657-D108-4B9E-B9CE-388DEAA33F36Q26773653-7B4780EA-092C-4942-A5E1-070AA6CBE6E0Q26777163-D61AF990-CDDF-4507-8F79-DF83B6DBE616Q26778913-4AF57D3E-FD7D-4915-8618-28EC55DF863BQ26786543-47988923-0B78-453E-904F-367C97D3F8D7Q26852579-41D13F64-6CBC-4ABA-B5BC-CF9F0437F1EDQ26853635-1E5BF5D7-CC01-4011-951D-50322D6C43FCQ26853735-2C058F17-0EE9-4284-A8C8-81A39630E670Q26996477-1BC31E74-6576-4391-BFA6-C87A8D4D01A7Q27008262-AD9E5624-0C13-43F8-A5BA-BFAEFEE848A8Q27013843-EB825283-D49B-42F2-9494-B11F83EE80A3Q27313709-0F9B6229-C287-4574-9BF3-B956DD88B1B4Q27347240-8C752A10-6A45-4980-8127-002347D5F4B3Q27348129-1D1670A7-9A53-426F-B634-331360DED05DQ27350187-18C8CB2B-CAAA-4EBE-8996-F098CBEC70D6Q27648698-232A1528-5D3F-49E4-9150-8DBB91104828Q28076745-5971BF7C-3417-4C59-8D6A-7D2F2E37C326Q28076820-96AAD839-BAFC-47CB-B445-719715595542Q28298412-C205B0F8-5D0F-4E66-9F7D-E22E1D98B186Q28388750-585E9826-BF31-423F-9018-0D8870B15032Q28479062-80F87560-B725-4697-8DE7-F745D1BC0A24Q28483635-1899CEFC-894B-49F6-8C73-A675FBE1FDE3Q28487784-F44C9C43-47D1-4A7D-8D38-DB7894E0E3A1Q28743074-E874197A-EF01-45A9-9602-C45D78B32BB4Q29617512-5A6A3DAE-805C-4A0A-9DC7-8F5ED5E8791CQ30277664-92CE6573-9F6C-41EF-B53D-528EB941179CQ30352713-11F92FB6-E0BD-4659-B47B-8E1AB7A38226
P2860
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Biology of progressive, castra ...... rogen-receptor signaling axis.
@ast
Biology of progressive, castra ...... rogen-receptor signaling axis.
@en
type
label
Biology of progressive, castra ...... rogen-receptor signaling axis.
@ast
Biology of progressive, castra ...... rogen-receptor signaling axis.
@en
prefLabel
Biology of progressive, castra ...... rogen-receptor signaling axis.
@ast
Biology of progressive, castra ...... rogen-receptor signaling axis.
@en
P356
P1476
Biology of progressive, castra ...... rogen-receptor signaling axis.
@en
P2093
Charles L Sawyers
Howard I Scher
P304
P356
10.1200/JCO.2005.03.4777
P407
P577
2005-11-01T00:00:00Z